Additionally, the presence of tumor-specific CD8+ splenic lymphocytes was significantly higher in dually treated animals compared to the other treatment groups, indicating the ability of this treatment approach to generate a systemic adaptive anti-tumor response (Figure 4F). The gene discussed is CD8A; the disease is neoplasm.